AccScience Publishing / GPD / Online First / DOI: 10.36922/GPD026290026
Cite this article
2
Download
41
Views
Related Info Links
More by Authors Links
Journal Browser
Volume | Year
Issue
Search
News and Announcements
View All
PERSPECTIVE ARTICLE

Zinc, albumin, frailty, and drug safety in long-term care residents: A translational perspective

Norifumi Kudeken1*
Show Less
1 Kubagawa Medical Clinic, Naha, Okinawa , Japan
Received: 18 July 2026 | Revised: 21 October 2026 | Accepted: 21 October 2026 | Published online: 18 November 2026
© 2026 by the Auhtor(s). This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution 4.0 International License ( https://creativecommons.org/licenses/by/4.0/ )
Abstract

Older residents of long-term care facilities (LTCFs) are increasingly treated with complex pharmacotherapy while living with frailty, malnutrition, inflammation, recurrent infection, and reduced physiological reserve. Medication safety in this population cannot rely only on chronological age, diagnostic labels, renal function, or medication counts. This article proposes a translational framework in which serum zinc and albumin are interpreted with frailty and medication review to identify residents at increased risk of adverse drug reactions, infection-related prescribing, and prescribing cascades. Zinc links nutritional status with immune signaling, antioxidant defense, tissue repair, protein synthesis, and gene-regulatory pathways, whereas albumin links plasma zinc transport, inflammation, and pharmacokinetic vulnerability. Because both markers are routinely measurable, they may support individualized clinical management in LTCFs. The proposed approach is not a dosing algorithm, but a practical strategy for integrating biological vulnerability into safer prescribing, deprescribing, monitoring, and nutritional care.

Keywords
Zinc; Albumin
Frailty
Drug safety
Long-term care
Older adults
Pharmacokinetics
Biological markers
Funding
None.
Conflict of interest
The author declares no conflicts of interest.
References
  1. Kudeken N. Low serum zinc levels among residents of a long-term care facility in Okinawa, Japan: a five-year descriptive open-cohort study using routinely collected measurements. Aging Med Healthc. Accepted May 23, 2026. In press.
  2. Kudeken N. Persistent zinc deficiency among residents of a long-term care facility: a five-year longitudinal study. Cureus. 2026;18(4):e107317. doi: 10.7759/cureus.107317
  3. Méndez-Guerrero O, Carranza-Carrasco A, Guerrero-Guerrero R, et al. Zinc deficiency and sarcopenia define a metabolic frailty phenotype predicting hepatic encephalopathy and early mortality in cirrhosis. Metab Brain Dis. 2026;41(1):117. doi: 10.1007/s11011-026-01879-9
  4. Farid M, Blasdel N, Wang J, et al. Benchmarking risk prediction tools in spine surgery: a national registry analysis of albumin, frailty, and surgical calculators. J Neurosurg Spine. 2026;45(3):467-481. doi: 10.3171/2026.2.SPINE251657
  5. Abeywickrama HM, Uchiyama M, Sumiyoshi T, Okuda A, Koyama Y. The role of zinc on nutritional status, sarcopenia, and frailty in older adults: a scoping review. Nutr Rev. 2024;82(7):988-1011. doi: 10.1093/nutrit/nuad094
  6. Wessels I, Maywald M, Rink L. Zinc as a gatekeeper of immune function. Nutrients. 2017;9(12):1286. doi: 10.3390/nu9121286
  7. Meydani SN, Barnett JB, Dallal GE, et al. Serum zinc and pneumonia in nursing home elderly. Am J Clin Nutr. 2007;86(4):1167-1173. doi: 10.1093/ajcn/86.4.1167
  8. Blindauer CA, Harvey I, Bunyan KE, et al. Structure, properties, and engineering of the major zinc binding site on human albumin. J Biol Chem. 2009;284(34):23116-23124. doi: 10.1074/jbc.M109.003459
  9. Idasiak-Piechocka I, Lewandowski D, Swigut W, et al. Effect of hypoalbuminemia on drug pharmacokinetics. Front Pharmacol. 2025;16:1546465. doi: 10.3389/fphar.2025.1546465
  10. Kudeken N. Prognostic nutritional index: a comprehensive review across clinical specialties. Clin Nutr Open Sci. 2026;66:100601. doi: 10.1016/j.nutos.2025.11.008
  11. Kim DH, Rockwood K. Frailty in older adults. N Engl J Med. 2024;391(6):538-548. doi: 10.1056/NEJMra2301292
  12. Pazan F, Wehling M. Polypharmacy in older adults: a narrative review of definitions, epidemiology and consequences. Eur Geriatr Med. 2021;12(3):443-452. doi: 10.1007/s41999-021-00479-3
  13. Zazzara MB, Palmer K, Vetrano DL, Carfi A, Onder G. Adverse drug reactions in older adults: a narrative review of the literature. Eur Geriatr Med. 2021;12(3):463-473. doi: 10.1007/s41999-021-00481-9
  14. Semla PT, Steinman M, Beizer J, et al. American Geriatrics Society 2023 updated AGS Beers Criteria® for potentially inappropriate medication use in older adults. J Am Geriatr Soc. 2023;71(7):2052-2081. doi: 10.1111/jgs.18372
  15. O’Mahony D, Cherubini A, Guiteras AR, et al. STOPP/START criteria for potentially inappropriate prescribing in older people: version 3. Eur Geriatr Med. 2023;14(4):625-632. doi: 10.1007/s41999-023-00777-y
  16. National Institutes of Health. Zinc. Nih.gov. Published September 28, 2022. Accessed June 10, 2026. https://ods.od.nih.gov/factsheets/Zinc-HealthProfessional/
Share
Back to top
Gene & Protein in Disease, Electronic ISSN: 2811-003X Published by AccScience Publishing